БАЗИГІН ЯК ПУХЛИНОАСОЦІЙОВАНИЙ ГЛІКОПРОТЕЇН ТА ЙОГО ПРОГНОСТИЧНЕ ЗНАЧЕННЯ
DOI:
https://doi.org/10.15407/oncology.2025.01.013Ключові слова:
CD147, стійкість до аноїкозу, пошкодження ДНК, стовбурові пухлинні клітини, традиційні протипухлинні препарати, променева терапія, прогностичний біомаркер, рідини організму, доклінічні дослідження, клінічні даніАнотація
Базигін (також відомий як TCSF, EMMPRIN, CD147 або HAb18G) є трансмембранним глікопротеїном I типу, що належить до надродини імуноглобулінів. Існують щонайменше чотири ізоформи базигіну людини, які утворюються шляхом альтернативного сплайсингу, з базигіном-2 (BSG) як прототиповою ізоформою. BSG посттрансляційно модифікується через N-глікозилювання та існує у високо- або низькоглікозильованих формах. На додачу до трансмембранної форми, BSG також вивільняється з клітин у секретованій формі (через відокремлення з поверхні клітин ектодомену після його протеолітичного відщеплення) або у повнорозмірній формі у складі позаклітинних везикулів. Окрім участі у регулюванні широкого спектра фізіологічних процесів, BSG надмірно експресується в багатьох типах злоякісних новоутворень та залучений до ключових шляхів або процесів, пов’язаних з прогресією онкологічного захворювання та розвитком рецидивів. Цей огляд сфокусований на важливому значенні BSG у регуляції проліферації, апоптозу, міграції та інвазії пухлинних клітин, епітеліально-мезенхімального переходу, виживаності пухлинних стовбурових клітин, пухлинному ангіогенезі та лімфангіогенезі, метастатичній дисемінації пухлинних клітин, ухилянні від протипухлинного імунітету та розвитку стійкості до лікувальних заходів. Крім того, коротко обговорюється прогностичне значення як трансмембранних, так й секретованих форм BSG для різних форм злоякісних новоутворень.
Посилання
Biswas C. Tumor cell stimulation of collagenase produc- tion by fi oblasts. Biochem Biophys Res Commun 1982; 109 (3): 1026–34. https://doi.org/10.1016/0006-291x(82) 92042-3.
Biswas C. Collagenase stimulation in cocultures of human fibroblasts and human tumor cells. Cancer Lett 1984; 24 (2): 201–7. https://doi.org/10.1016/0304-3835(84)90137-x.
Ellis SM, Nabeshima K, Biswas C. Monoclonal antibody preparation and purifi ation of a tumor cell collagenase- stimulatory factor. Cancer Res 1989; 49 (12): 3385–91. PMID: 2541902.
Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell- derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55 (2): 434–9. PMID: 7812975.
Miyauchi T, Kanekura T, Yamaoka A, et al. Basigin, a new, broadly distributed member of the immunoglobulin super- family, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class II antigen. J Biochem 1990; 107 (2): 316–23. https://doi.org/10.1093/oxfordjournals.jbchem.a123045.
Koch C, Majdic O, Prager E, et al. In: Kishimoto T, Kikuta- ni H, vond dem Borne AEGK, eds. Leukocyte Typing VI: White Cell Differentiation Antigens. New York & London: Garland Publishing, Inc., 1997: 760–3.
Muramatsu T. Basigin (CD147), a multifunctional trans- membrane glycoprotein with various binding partners. J Biochem 2016; 159 (5): 481–90. https://doi.org/10.1093/ jb/mvv127.
Landras A, Reger de Moura C, Jouenne F, et al. CD147 is a promising target of tumor progression and a prognostic biomarker. Cancers (Basel) 2019; 11 (11): 1803. https://doi. org/10.3390/cancers11111803.
Yoshida S, Shibata M, Yamamoto S, et al. Homo-oligomer formation by basigin, an immunoglobulin superfamily member, via its N-terminal immunoglobulin domain. Eur J Biochem 2000; 267 (14): 4372–80. https://doi.org/10.1046/ j.1432-1327.2000.01482.x.
Schmidt R, Bültmann A, Fischel S, et al. Extracellular mat- rix metalloproteinase inducer (CD147) is a novel recep- tor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008; 102 (3): 302–9. https://doi.org/10.1161/ CIRCRESAHA.107.157990.
Li R, Huang L, Guo H, et al. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fi o- blasts. J Cell Physiol 2001; 186 (3): 371–9. https://doi. org/10.1002/1097-4652(2000)9999:999<000::AID-JCP 1042>3.0.CO;2-8.
Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metallo- proteinase inducer interactions. Cancer Res 2001; 61 (5): 2276–81. PMID: 11280798.
Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002; 21 (37): 5765–72. https://doi. org/10.1038/sj.onc.1205702.
Egawa N, Koshikawa N, Tomari T, et al. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem 2006; 281 (49): 37576–85. https://doi.org/10.1074/ jbc.M606993200.
Zhang W, Zhao P, Xu XL, et al. Annexin A2 promotes the mig- ration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring mic- rovesicles from tumor cells. PLoS One 2013; 8 (8): e67268. https://doi.org/10.1371/journal.pone.0067268.
Knutti N, Kuepper M, Friedrich K. Soluble extracellular matrix metalloproteinase inducer (EMMPRIN, EMN) regulates cancer-related cellular functions by homotypic interactions with surface CD147. FEBS J 2015; 282 (21): 4187–200. https://doi.org/10.1111/febs.13414.
Grass GD, Toole BP. How, with whom and when: An over- view of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep 2015; 36 (1): e00283. https://doi.org/10.1042/BSR20150256.
Heinzmann D, Noethel M, Ungern-Sternberg SV, et al. CD147 is a novel interaction partner of integrin αMβ2 me- diating leukocyte and platelet adhesion. Biomolecules 2020; 10 (4): 541. https://doi.org/10.3390/biom10040541.
Han JM, Jung HJ. Cyclophilin A/CD147 interaction: A promising target for anticancer therapy. Int J Mol Sci 2022; 23 (16): 9341. https://doi.org/10.3390/ij 3169341.
Peng J, Jiang H, Guo J, et al. CD147 expression is associated with tumor proliferation in bladder cancer via GSDMD. Biomed Res Int 2020; 2020: 7638975. https://doi.org/10. 1155/2020/7638975.
Bougatef F, Menashi S, Khayati F, et al. EMMPRIN pro- motes melanoma cells malignant properties through a HIF- 2alpha mediated up-regulation of VEGF-receptor-2. PLoS One 2010; 5 (8): e12265. https://doi.org/10.1371/journal. pone.0012265.
Huang Q, Li J, Xing J, et al. CD147 promotes reprogram- ming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. J Hepatol 2014; 61 (4): 859–66. https://doi.org/10.1016/j. jhep.2014.04.035.
Chen L, Pan Y, Gu L, et al. ERK1/2 signalling pathway is involved in CD147-mediated gastric cancer cell line
SGC7901 proliferation and invasion. Exp Biol Med (May- wood) 2013; 238 (8): 903–12. https://doi.org/10.1177/
Schneiderhan W, Scheler M, Holzmann KH, et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 2009; 58 (10): 1391–8. https://doi.org/10.1136/ gut.2009.181412.
Zhang N, Liu Z, Lai X, et al. Silencing of CD147 inhibits cell proliferation, migration, invasion, lipid metabolism dys- regulation and promotes apoptosis in lung adenocarcinoma via blocking the Rap1 signaling pathway. Respir Res 2023; 24 (1): 253. https://doi.org/10.1186/s12931-023-02532-0.
Zou S, Parfenova E, Vrdoljak N, et al. Pseudolaric acid B tar- gets CD147 to selectively kill acute myeloid leukemia cells. Int J Mol Sci 2024; 25 (12): 6517. https://doi.org/10.3390/ ij 126517.
Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Im- munol 2020; 38: 567–95. https://doi.org/10.1146/annurev- immunol-073119-095439.
Wang C, Xu C, Niu R, et al. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147. BMC Cancer 2019; 19 (1): 577. https://doi.org/10.1186/s12885-019-5796-9.
Pan Y, Sun H, Hu X, et al. The inhibitory role of miR-485-5p in colorectal cancer proliferation and invasion via targeting of CD147. Oncol Rep 2018; 39 (5): 2201–8. https://doi. org/10.3892/or.2018.6309.
Li M, Zhai Q, Bharadwaj U, et al. Cyclophilin A is overex- pressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006; 106 (10): 2284–94. https://doi.org/10.1002/cncr.21862.
Yin H, Shao Y, Chen X. The effects of CD147 on the cell pro- liferation, apoptosis, invasion, and angiogenesis in glioma. Neurol Sci 2017; 38 (1): 129–36. https://doi.org/10.1007/ s10072-016-2727-2.
Fu ZG, Wang Y, Wang S, et al. Synthesis and evaluation of a novel small-molecule compound as an anticancer inhibi- tor of CD147. Biomed Environ Sci 2019; 32 (9): 673–86. https://doi.org/10.3967/bes2019.086.
Ke X, Li L, Dong HL, Chen ZN. Acquisition of anoikis re- sistance through CD147 upregulation: A new mechanism underlying metastasis of hepatocellular carcinoma cells. Oncol Lett 2012; 3 (6): 1249–54. https://doi.org/10.3892/ ol.2012.658.
Yang JM, O’Neill P, Jin W, et al. Extracellular matrix metal- loproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem 2006; 281 (14): 9719–27. https://doi.org/10.1074/ jbc.M508421200.
Guindolet D, Gabison EE. Role of CD147 (EMMPRIN/ basigin) in tissue remodeling. Anat Rec (Hoboken) 2020; 303 (6): 1584–9. https://doi.org/10.1002/ar.24089.
Nishibaba R, Higashi Y, Su J, et al. CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant mela- noma cells by phosphorylating focal adhesion kinase. J Dermatol 2012; 39 (1): 63–7. https://doi.org/10.1111/ j.1346-8138.2011.01304.x.
Dana P, Kariya R, Vaeteewoottacharn K, et al. Upregulation of CD147 promotes metastasis of cholangiocarcinoma by modulating the epithelial-to-mesenchymal transitional process. Oncol Res 2017; 25 (7): 1047–59. https://doi.org
/10.3727/096504016X14813899000565.
Guo W, Abudumijiti H, Xu L, et al. CD147 promotes cervical cancer migration and invasion by up-regulating fatty acid synthase expression. Int J Clin Exp Pathol 2019; 12 (12): 4280–8. PMID: 31933828.
Min A, Xiong H, Wang W, et al. CD147 promotes proliferation and migration of oral cancer cells by inhibiting junctions be- tween E-cadherin and β-catenin. J Oral Pathol Med 2020; 49 (10): 1019–29. https://doi.org/10.1111/jop.13088.
Xu J, Lu Y, Qiu S, et al. A novel role of EMMPRIN/CD147 in transformation of quiescent fi oblasts to cancer-associ- ated fibroblasts by breast cancer cells. Cancer Lett 2013; 335 (2): 380–6. https://doi.org/10.1016/j.canlet.2013.02.054.
Takahashi M, Suzuki S, Ishikawa K. Cyclophilin A-EMMPRIN interaction induces invasion of head and neck squamous cell carcinoma. Oncol Rep 2012; 27 (1): 198–203. https:// doi.org/10.3892/or.2011.1474.
Toyoma S, Suzuki S, Kawasaki Y, et al. SDF-1/CXCR4 induces cell invasion through CD147 in squamous cell carcinoma of the hypopharynx. Oncol Lett 2020; 20 (2): 1817–23. https://doi.org/10.3892/ol.2020.11744.
Wang SJ, Chao D, Wei W, et al. CD147 promotes collec- tive invasion through cathepsin B in hepatocellular carci- noma. J Exp Clin Cancer Res 2020; 39 (1): 145. https:// doi.org/10.1186/s13046-020-01647-2.
Wu J, Ru NY, Zhang Y, et al. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signal- ing and is transcriptionally regulated by Slug. Oncogene 2011; 30 (43): 4410–27. https://doi.org/10.1038/onc.2011. 149.
Fang F, Li Q, Wu M, et al. CD147 promotes epithelial-me- senchymal transition of prostate cancer cells via the Wnt/β- catenin pathway. Exp Ther Med 2020; 20 (4): 3154–60. https://doi.org/10.3892/etm.2020.9058.
Suzuki S, Toyoma S, Tsuji T, et al. CD147 mediates trans- forming growth factor-β1-induced epithelial-mesenchymal transition and cell invasion in squamous cell carcinoma of the tongue. Exp Ther Med 2019; 17 (4): 2855–60. https:// doi.org/10.3892/etm.2019.7230.
Li F, Wang J, Yan YQ, et al. CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/ERK signaling pathway. BMC Cancer 2023; 23 (1): 1214. https://doi.org/10.1186/s12885- 023-11724-2.
Wu X, Qiao B, Liu Q, et al. Upregulation of extracellu- lar matrix metalloproteinase inducer promotes hypoxia- induced epithelial-mesenchymal transition in esophageal cancer. Mol Med Rep 2015; 12 (5): 7419–24. https://doi. org/10.3892/mmr.2015.4410.
Lu M, Wu J, Hao ZW, et al. Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress. Hepa- tology 2018; 68 (1): 317–32. https://doi.org/10.1002/hep. 29798.
Philchenkov A, Dubrovska A. Cancer stem cells as a thera- peutic target: Current clinical development and future pros- pective. Stem Cells 2024; 42 (3): 173–99. https://doi.org/ 10.1093/stmcls/sxad092.
Dai L, Guinea MC, Slomiany MG, et al. CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells. Am J Pathol 2013; 182 (2): 577–85. https:// doi.org/10.1016/j.ajpath.2012.10.011.
Kang MJ, Kim HP, Lee KS, et al. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells. Proteomics 2013; 13 (10-11): 1714–25. https://doi.org/10.1002/pmic.201200511.
Liu Y, Cui P, Chen J, et al. Isolation and phenotypic charac- terization of side population cells in oral squamous cell carcinoma. Mol Med Rep 2015; 11 (5): 3642–6. https:// doi.org/10.3892/mmr.2014.3133.
Mohanta S, Siddappa G, Valiyaveedan SG, et al. Cancer stem cell markers in patterning differentiation and in prognosis of oral squamous cell carcinoma. Tumour Biol
; 39 (6): 1010428317703656. https://doi.org/10.1177/
Jiang Y, Liang R, Li L, et al. Studies on the effect and mechanism of CD147 on melanoma stem cells. Allergol Immunopathol (Madr) 2024; 52 (1): 71–8. https://doi.org/ 10.15586/aei.v52i1.1018.
Fan XY, He D, Sheng CB, et al. Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells. Am J Transl Res 2019; 11 (6): 3543–54. PMID: 31312365.
Chen J, Pan Y, He B, et al. Inhibition of CD147 expression by RNA interference reduces proliferation, invasion and increases chemosensitivity in cancer stem cell-like HT-29 cells. Int J Oncol 2015; 47 (4): 1476–84. https://doi.org/ 0.3892/ij 15.3138.
Meng Y, Fan XY, Yang LJ, et al. Detachment activated CyPA/CD147 induces cancer stem cell potential in non- stem breast cancer cells. Front Cell Dev Biol 2020; 8: 543856. https://doi.org/10.3389/fcell.2020.543856.
Spinello I, Saulle E, Quaranta MT, et al. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemo- therapeutic sensitivity of acute myeloid leukemia cells. Hae- matologica 2019; 104 (5): 973–85. https://doi.org/10.3324/ haematol.2018.199661.
Ivanivska TS, Sklyarenko LM, Zavelevich MP, et al. Immu- nophenotypic features of leukemic stem cells and bulk of blasts in acute myeloid leukemia. Exp Oncol 2019; 41 (3): 207–9. https://doi.org/10.32471/exp-oncology.2312-8852. vol-41-no-3.13492.
Bergers G, Brekken R, McMahon G, et al. Matrix metallo- proteinase-9 triggers the angiogenic switch during carcino- genesis. Nat Cell Biol 2000; 2 (10): 737–44. https://doi. org/10.1038/35036374.
Fang J, Shing Y, Wiederschain D, et al. Matrix metallo- proteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000; 97 (8): 3884–9. https://doi.org/10.1073/pnas.97.8. 3884.
Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and mat- rix metalloproteinases. Cancer Res 2005; 65 (8): 3193–9. https://doi.org/10.1158/0008-5472.CAN-04-3605.
Bougatef F, Quemener C, Kellouche S, et al. EMMPRIN promotes angiogenesis through hypoxia-inducible factor- 2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 2009; 114 (27): 5547–56. https://doi.org/10.1182/blood-2009-04-217380.
Khayati F, Pérez-Cano L, Maouche K, et al. EMMPRIN/ CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. Oncotarget 2015; 6 (12): 9766–80. https://doi.org/10.18632/oncotarget.2870.
Quemener C, Gabison EE, Naïmi B, et al. Extracellular matrix metalloproteinase inducer up-regulates the uroki- nase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007; 67 (1): 9–15. https://doi. org/10.1158/0008-5472.CAN-06-2448.
Millimaggi D, Mari M, D’Ascenzo S, et al. Tumor vesicle- associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007; 9 (4): 349–57. https:// doi.org/10.1593/neo.07133.
Chen Y, Gou X, Ke X, et al. Human tumor cells induce an- giogenesis through positive feedback between CD147 and insulin-like growth factor-I. PLoS One 2012; 7 (7): e40965. https://doi.org/10.1371/journal.pone.0040965.
Reger de Moura C, Landras A, Khayati F, et al. CD147 pro- motes tumor lymphangiogenesis in melanoma via PROX-1.
Cancers (Basel) 2021; 13 (19): 4859. https://doi.org/10.
/cancers13194859.
Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer 2021; 124 (1): 13–26. https://doi.org/10.1038/s41416-020- 01161-4.
Philchenkov AA. Molecular mechanisms of the metastasizing process. Oncology (Kyiv) 1999; 1 (2): 122–35 (in Rus- sian).
Sidhu SS, Nawroth R, Retz M, et al. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a poten- tial role in accelerating lung tumorigenesis. Oncogene 2010; 29 (29): 4145–56. https://doi.org/10.1038/onc.2010.166.
Hamidi H, Ivaska J. Every step of the way: Integrins in cancer progression and metastasis. Nat Rev Cancer 2018; 18 (9): 533–48. https://doi.org/10.1038/s41568-018-0038-z.
Feigelman G, Simanovich E, Brockmeyer P, et al. EMMPRIN promotes spheroid organization and metastatic formation: Comparison between monolayers and spheroids of CT26 colon carcinoma cells. Front Immunol 2024; 15: 1374088. https://doi.org/10.3389/fi 1374088.
Klein CA, Seidl S, Petat-Dutter K, et al. Combined trans- criptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002; 20 (4): 387–92. https://doi. org/10.1038/nbt0402-387.
Reimers N, Zafrakas K, Assmann V, et al. Expression of extra- cellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10 (10): 3422–8. https://doi.org/10.1158/1078-0432. CCR-03-0610.
Liu B, Wan Z, Sheng B, et al. Overexpression of EMMPRIN is associated with lymph node metastasis and advanced stage of non-small cell lung cancer: A retrospective study. BMC Pulm Med 2017; 17 (1): 214. https://doi.org/10.1186/ s12890-017-0540-1.
Suzuki S, Honda K, Nanjo H, et al. CD147 expression cor- relates with lymph node metastasis in T1-T2 squamous cell carcinoma of the tongue. Oncol Lett 2017; 14 (4): 4670–6. https://doi.org/10.3892/ol.2017.6808.
Li F, Zhang J, Guo J, et al. RNA interference targeting CD147 inhibits metastasis and invasion of human breast cancer MCF-7 cells by downregulating MMP-9/VEGF expression. Acta Biochim Biophys Sin 2018; 50 (7): 676–84. https://doi.org/10.1093/abbs/gmy062.
Wang M, Zhang S, Sun Q, et al. Dual eff of an anti- CD147 antibody for esophageal cancer therapy. Cancer Biol Ther 2019; 20 (12): 1443–52. https://doi.org/10.1080/ 15384047.2019.1647052.
Li W, Wang D, Ge Y, et al. Discovery and biological evalua- tion of CD147 N-glycan inhibitors: A new direction in the treatment of tumor metastasis. Molecules 2020; 26 (1): 33. https://doi.org/10.3390/molecules26010033.
Liu C, Zhao Q, Yu X. Bone marrow adipocytes, adipocyto- kines, and breast cancer cells: Novel implications in bone metastasis of breast cancer. Front Oncol 2020; 10: 561595. https://doi.org/10.3389/fonc.2020.561595.
Liao CG, Yao L, Xie W, et al. Basigin-2 upregulated by recep- tor activator of NF-κB ligand enhances lung cancer-induced osteolytic lesions. Cancer Cell Int 2016; 16: 28. https://doi. org/10.1186/s12935-016-0302-9.
Philchenkov AA. Bone marrow adipocytes and multiple mye- loma. Oncohematology 2019; 14 (1): 60–75. https://doi. org/10.17650/1818-8346-2019-14-1-60-75.
Perera CN, Chin HG, Duru N, et al. Leptin-regulated gene expression in MCF-7 breast cancer cells: Mechanistic in- sights into leptin-regulated mammary tumor growth and progression. J Endocrinol 2008; 199 (2): 221–33. https:// doi.org/10.1677/JOE-08-0215.
Kasinrerk W, Fiebiger E, Stefanová I, et al. Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J Immunol 1992; 149 (3): 847–54. PMID: 1634773.
Li X, Zhang Y, Ma W, et al. Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma. Cancer Immunol Immunother 2020; 69 (4): 535–48. https://doi.org/10.1007/s00262-019- 02457-y.
Chen Y, Xu J, Wu X, et al. CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape. Cell Mol Immunol 2021; 18 (8): 1995–2009. https://doi.org/10. 1038/s41423-020-00570-y.
Zhou S, Liao L, Chen C, et al. CD147 mediates chemoresis- tance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett 2013; 337 (2): 285–92. https://doi.org/10.1016/j.canlet.2013.04.025.
Wang WJ, Li QQ, Xu JD, et al. Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 2008; 54 (4): 291–301. https://doi.org/10.1159/000151225.
Gluzman DF, Philchenkov AA, Ivanovskaya TS. Cell surface molecular markers for identification of cancer stem cell populations (systematic review). Probl Oncol 2020; 66 (4): 336–45. https://doi.org/10.37469/0507-3758-2020-66-4- 336-345.
Zhao S, Wu L, Kuang Y, et al. Downregulation of CD147 in- duces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression. Int J Oncol 2018; 53 (6): 2397–408. https://doi.org/10.3892/ij 18.4579.
Zhou Y, Zheng M, Liu Z, et al. CD147 promotes DNA dam- age response and gemcitabine resistance via targeting ATM/ ATR/p53 and aff prognosis in pancreatic cancer. Bio- chem Biophys Res Commun 2020; 528 (1): 62–70. https:// doi.org/10.1016/j.bbrc.2020.05.005.
Kuang Y, Wang S, Tang L, et al. Cluster of diff rentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H+-ATPase expression and activity. Oncol Lett 2018; 15 (5): 7279–90. https://doi.org/10.3892/ol.2018. 8199.
Tang J, Guo YS, Zhang Y, et al. CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma. Cell Death Diff r 2012; 19 (11): 1779–90. https://doi.org/10.1038/ cdd.2012.60.
Qian M, Wan Z, Liang X, et al. Targeting autophagy in HCC treatment: Exploiting the CD147 internalization pathway. Cell Commun Signal 2024; 22 (1): 583. https:// doi.org/10.1186/s12964-024-01956-5.
Nan G, Zhao SH, Wang T, et al. CD147 supports pacli- taxel resistance via interacting with RanBP1. Oncogene 2022; 41 (7): 983–96. https://doi.org/10.1038/s41388-021- 02143-3.
Huang Z, Wang L, Wang Y, et al. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J Oral Pathol Med 2013; 42 (7): 541–6. https://doi.org/10.1111/jop.12046.
Ma C, Wang J, Fan L, et al. Inhibition of CD147 expression promotes chemosensitivity in HNSCC cells by deactivating MAPK/ERK signaling pathway. Exp Mol Pathol 2017; 102 (1): 59–64. https://doi.org/10.1016/j.yexmp.2017.01.002.
Afonso J, Santos LL, Miranda-Gonçalves V, et al. CD147 and MCT1-potential partners in bladder cancer aggressive- ness and cisplatin resistance. Mol Carcinog 2015; 54 (11): 1451–66. https://doi.org/10.1002/mc.22222.
Bu X, Qu X, Guo K, et al. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2
pathway. Int J Biol Sci 2021; 17 (12): 3013–23. https://doi. org/10.7150/ij s.60894.
Somno A, Anuchapreeda S, Chruewkamlow N, et al. In- volvement of CD147 on multidrug resistance through the regulation of P-glycoprotein expression in K562/ADR leu- kemic cell line. Leuk Res Rep 2016; 6: 33–8. https://doi. org/10.1016/j.lrr.2016.08.001.
Xiong L, Ding L, Ning H, et al. CD147 knockdown im- proves the antitumor effi acy of trastuzumab in HER2- positive breast cancer cells. Oncotarget 2016; 7 (36): 57737–
https://doi.org/10.18632/oncotarget.10252.
Tabolacci C, Cordella M, Mariotti S, et al. Melanoma cell resistance to vemurafenib modifi inter-cellular commu- nication signals. Biomedicines 2021; 9 (1): 79. https://doi. org/10.3390/biomedicines9010079.
Shen L, Xia M, Deng X, et al. A lectin-based glycomic approach identifi FUT8 as a driver of radioresistance in oesophageal squamous cell carcinoma. Cell Oncol (Dordr) 2020; 43 (4): 695–707. https://doi.org/10.1007/s13402-020- 00517-5.
Ju X, Liang S, Zhu J, et al. Extracellular matrix metal- loproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the per- centage of the cells in the G2/M phase of the cell cycle and the repair of DNA double-strand breaks (DSBs). Am J Transl Res 2016; 8 (6): 2498–511. PMID: 27398135.
Li L, Dong X, Peng F, et al. Integrin β1 regulates the inva- sion and radioresistance of laryngeal cancer cells by tar- geting CD147. Cancer Cell Int 2018; 18: 80. https://doi. org/10.1186/s12935-018-0578-z.
Wu J, Li Y, Dang YZ, et al. HAb18G/CD147 promotes ra- dioresistance in hepatocellular carcinoma cells: A potential role for integrin β1 signaling. Mol Cancer Ther 2015; 14 (2): 553–63. https://doi.org/10.1158/1535-7163.MCT-14- 0618.
Domina EA, Philchenkov A, Dubrovska A. Individual re- sponse to ionizing radiation and personalized radiothe- rapy. Crit Rev Oncog 2018; 23 (1–2): 69–92. https://doi. org/10.1615/CritRevOncog.2018026308.
Song Q, Wen J, Li W, et al. HSP90 promotes radioresis- tance of cervical cancer cells via reducing FBXO6-me- diated CD147 polyubiquitination. Cancer Sci 2022; 113 (4): 1463–74. https://doi.org/10.1111/cas.15269.
Zheng HC, Gong BC. CD147 expression was positively linked to aggressiveness and worse prognosis of gastric can- cer: A meta and bioinformatics analysis. Oncotarget 2017; 8 (52): 90358–70. https://doi.org/10.18632/oncotarget. 20089.
Shi S, Ma HY, Sang YZ, et al. CD147 expression as a clini- copathological and prognostic indicator in breast cancer: A meta-analysis and bioinformatics analysis. BMC Cancer 2024; 24 (1): 1429. https://doi.org/10.1186/s12885-024- 13202-9.
Huang X, Shen W, Xi H, et al. Prognostic role of extracel- lular matrix metalloproteinase inducer/CD147 in gastroin- testinal cancer: A meta-analysis of related studies. Onco- target 2016; 7 (49): 81003–11. https://doi.org/10.18632/ oncotarget.12745.
Li H, Xu Y, Li H. CD147 as a novel biomarker for predicting the prognosis and clinicopathological features of bladder cancer: A meta-analysis. Oncotarget 2017; 8 (37): 62573–88. https://doi.org/10.18632/oncotarget.19257.
Peng F, Li H, Ning Z, et al. CD147 and prostate cancer: A systematic review and meta-analysis. PLoS One 2016; 11 (9): e0163678. https://doi.org/10.1371/journal.pone. 0163678.
Li H, Wu D, Shi S, et al. Expression and clinical significance of CD147 in renal cell carcinoma: A meta-analysis. Onco-
target 2017; 8 (31): 51331–44. https://doi.org/10.18632/ oncotarget.17376.
Li H, Jiang C, Wu D, et al. The prognostic and clinico- pathologic characteristics of CD147 and esophagus cancer: A meta-analysis. PLoS One 2017; 12 (7): e0180271. https:// doi.org/10.1371/journal.pone.0180271.
Zhang X, Tian T, Zhang X, et al. Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer. Oncotarget 2017; 8 (23): 37673–80. https:// doi.org/10.18632/oncotarget.16948.
Peng F, Li H, You Q, et al. CD147 as a novel prognostic biomarker for hepatocellular carcinoma: A meta-analysis. Biomed Res Int 2017; 2017: 5019367. https://doi.org/10. 1155/2017/5019367.
Li H, Xi Z, Dai X, et al. CD147 and glioma: A meta-analy- sis. J Neurooncol 2017; 134 (1): 145–56. https://doi.org/ 10.1007/s11060-017-2499-4.
Huang T, He WY. Pan-cancer analysis, reveals COVID-19- related BSG as a novel marker for treatment and identifica- tion of multiple human cancers. Front Cell Dev Biol 2022; 10: 876180. https://doi.org/10.3389/fcell.2022.876180.
Qiao X, Gu Y, Yu J, et al. The combination of CD147 and MMP-9 serum levels is identified as novel chemotherapy response markers of advanced non-small-cell lung can- cer. Dis Markers 2020; 2020: 8085053. https://doi.org/10. 1155/2020/8085053.
Kuang YH, Liu YJ, Tang LL, et al. Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance. Hong Kong Med J 2018; 24 (3): 252–60. https://doi.org/10.12809/hkmj176865.
Lee A, Rode A, Nicoll A, et al. Circulating CD147 pre- dicts mortality in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2016; 31 (2): 459–66. https://doi. org/10.1111/jgh.13148.
Boddu VK, Zamzow P, Kramer MW, et al. Targeting cancer- derived extracellular vesicles by combining CD147 inhibi- tion with tissue factor pathway inhibitor for the management
of urothelial cancer cells. Cell Commun Signal 2024; 22 (1): 129. https://doi.org/10.1186/s12964-024-01508-x.
Leung LL, Qu X, Chen B, et al. Extracellular vesicles in liquid biopsies: There is hope for oral squamous cell car- cinoma. Extracell Vesicles Circ Nucl Acids 2024; 5 (4): 639–59. https://doi.org/10.20517/evcna.2024.29.
Jackson HK, Mitoko C, Linke F, et al. Extracellular vesicles potentiate medulloblastoma metastasis in an EMMPRIN and MMP-2 dependent manner. Cancers (Basel) 2023; 15 (9): 2601. https://doi.org/10.3390/cancers15092601.
Zhang Z, Liu X, Yang X, et al. Identifi ation of faecal extracel- lular vesicles as novel biomarkers for the non-invasive diag- nosis and prognosis of colorectal cancer. J Extracell Vesicles 2023; 12 (1): e12300. https://doi.org/10.1002/jev2.12300.
Ma X, Liu T, Guo R, et al. Radioiodinated nanobody im- munoPET probe for in vivo detection of CD147 in pan-can- cer. Eur J Nucl Med Mol Imaging 2025; 52 (4): 1406–21. https://doi.org/10.1007/s00259-024-06985-3.
Moyano A, Serrano-Pertierra E, Duque JM, et al. Magnetic lateral fl w immunoassay for small extracellular vesicles quantification: Application to colorectal cancer biomarker detection. Sensors (Basel) 2021; 21 (11): 3756. https://doi. org/10.3390/s21113756.
Pérez-Ginés V, Torrente-Rodríguez RM, Montero-Calle A, et al. Tackling CD147 exosome-based cell-cell signaling by electrochemical biosensing for early colorectal cancer detection. Biosensors & Bioelectronics: X 2022; 11: 100192. https://doi.org/10.1016/j.biosx.2022.100192.
Gu C, Shang A, Liu G, et al. Identification of CD147-posi- tive extracellular vesicles as novel non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer. Clin Chim Acta 2023; 548: 117510. https://doi.org/10.1016/j. cca.2023.117510.
Ono M, Zhang H, Sone H, et al. Multiplex quantifi a- tion of exosomes via multiple types of nanobeads labeling combined with laser scanning detection. Anal Chem 2023; 95 (42): 15577–84. https://doi.org/10.1021/acs.analchem. 3c02374.
